![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
OncoArendi Therapeutics announced today that this week the Company will initiate a Phase 1 study designed to assess the safety, tolerability and pharmacokinetics of its lead
compound, OATD-01.
OncoArendi Therapeutics has been granted permission from the German Federal Institute for Drugs and Medical Devices (BfArM) to begin the first-in- human clinical valuation of its novel drug candidate.
OATD-01, a potent dual inhibitor of acidic mammalian chitinase (AMCase) and chitotriosidase (CHIT1), was developed as an innovative, oral therapy for the treatment of asthma. OATD-01 is the first drug candidate targeting members of the chitinase family to enter clinical development. The data obtained from the Phase 1 study will guide the design of the subsequent trial, planned to begin in 2018, where multiple ascending doses will be evaluated.
“The initiation of the Phase 1 clinical trial of OATD-01 is a major milestone, not only for the program, but also for the advancement of an entirely new class of drugs. It is also a significant milestone in the development of OncoArendi as it has now become a clinical-stage biotechnology company” said Marcin Szumowski, OncoArendi’s President and
CEO.
About the Phase 1 Healthy Volunteers Study
This Phase 1, randomized, double-blind, dose-escalation study will evaluate OATD-01 in placebo-controlled cohorts, enrolling up to 48 subjects. The objective of the study is to investigate safety, tolerability and pharmacokinetics in healthy male volunteers evaluated in several dose cohorts within the single dose-range study. The primary outcome measures will evaluate the safety and tolerability of OATD-01 by assessing the nature and frequency of adverse events (AEs), laboratory assessments and electrocardiogram (ECG). Secondary measures will investigate the pharmacokinetics of OATD-01.
“Our first dosing of OATD-01 represents the culmination of years of chemistry and biology discovery as well as chemical and preclinical development work. With the recent
discovery of the significant anti-fibrotic activity of OATD-01 we are very excited about the clinical prospects of the chitinase inhibitors in treatment of not only asthma but also
other interstitial lung diseases including idiopathic pulmonary fibrosis or sarcoidosis” said Stanislaw Pikul, VP of Development.
About OncoArendi Therapeutics
OncoArendi Therapeutics is an innovative biopharmaceutical company dedicated to developing and commercializing novel therapeutics for inflammatory diseases associated with tissue remodelling and cancer. OncoArendi has a broad interest and commitment to chitinase science with three distinct small molecule drug discovery programs targetting different chitinase family proteins currently in progress. Potential therapeutic applications for compounds resulting from this R&D Chitinase Platform include treatment of numerous diseases with high unmet medical need, such as asthma, idiopathic pulmonary fibrosis (IPF), sarcoidosis, as well as diseases associated with fibrosis of other organs and some types of cancer.
Contacts
Stanislaw Pikul
VP Development
s.pikul@oncoarendi.com
Marcin Szumowski
President & CEO
m.szumowski@oncoarendi.com
OncoArendi Therapeutics S.A.
Zwirki i Wigury 101
02-089 Warsaw
Poland
